Pfizer’s TUKYSA Shows Strong Results in First-Line HER2+ Breast Cancer Trial
Pfizer Inc. announced positive topline results from its Phase 3 HER2CLIMB-05 trial, marking a potential breakthrough in first-line treatment for patients with HER2-positive (HER2+)…
Read More...
Read More...
